Display Of IP Strength In China: Lilly Wins Patent Dispute For Cialis Against Domestic Chinese Company
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Eli Lilly's win of the patent infringement suit in China against Jiangyin Dongfang Pharmaceutical for manufacturing tadalafil, the active ingredient in Lilly's male erectile dysfunction drug Cialis, is good news for multinational companies operating in China
You may also be interested in...
Lilly Suzhou Pharmaceutical Expands Insulin Plant
Lilly Suzhou Pharmaceutical recently held a ground-breaking ceremony for its Suzhou plant expansion project. With an investment of more than $40 million, the plant will cover an area of 50,000 square meters, 60 percent bigger than the current factory, and will be used mainly for packaging and storing insulin products. After completion of the project, both the existing and new plants will produce insulin products. The new plant will help Lilly increase its insulin production capacity to meet China's growing pharmaceutical market needs. (Click here for more - Chinese Language)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).